Sermorelin
Also called GHRH (1-29), GRF (1-29)
What to know about Sermorelin
Sermorelin is the first 29 amino acids of human GHRH, the shortest sequence retaining substantial pituitary growth-hormone-releasing activity.
- How it may work
- It activates pituitary GHRH receptors, producing a growth-hormone pulse that depends on remaining pituitary capacity and normal feedback systems.
- What research found
- Human challenge studies established acute, dose-related growth-hormone responses. These short endocrine tests are not evidence for broad body-composition or longevity claims.
- What is not settled
- Published challenge studies are too short to characterize long-term endocrine, glucose, fluid-balance, or injection-related risks.
- Research and product status
- A prior U.S. sermorelin product was discontinued; current compounded material is not equivalent to an actively licensed branded product.
Research reference
- Research amount range
- 100–500 mcg per administration — not a starting amount
- Reference frequency
- Every day — catalogue input, not a personal schedule
- Evidence route
- Subcutaneous in the cited evidence; formulation matters. Sites and rotation
- Reported timing context
- Usually at night and fasted, to align with the body's own growth-hormone release.
- What people report
- Sleep and recovery contexts are discussed over the first weeks.
- Model accumulation timescale
- ~1 hours — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
- Reported course context
- 8–12 weeks
- Reported break context
- 4 weeks Why
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
- When change was measured
- Human studies mainly used sermorelin or GHRH(1-29) as an acute stimulation test and measured growth hormone over minutes to hours. They do not establish a sleep, recovery, or body-composition timeline.
- When to assess
- An acute laboratory response is not a validated personal outcome checkpoint. No strong long-duration trial supplies a week at which commonly claimed wellness results should be judged.
- Conditions and limitations
- The challenge-test literature does not establish bedtime use, fasting, or pairing with another secretagogue as necessary for a meaningful outcome.
- When to stop
- No general self-directed course length, maintenance phase, or quit rule follows from the acute studies. Lack of a felt response is not a reason to increase exposure.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Combination evidence and cautions
What is known and unknown about Sermorelin alongside other compounds or medicines.
Key properties
- Formula
- C149H246N44O42S
- Mol. weight
- 3,357.9 Da
- CAS
- 86168-78-7
- PubChem CID
- 16132413
External references
Structure note
A diagram is a reference representation of the named chemical structure. It does not establish the composition, purity, or identity of any particular vial.
Vial arithmetic
Published research contexts for Sermorelin describe 100–500 mcg per administration. Descriptive only, not a recommendation.
Roughly 11-12 minutes in plasma. One of the shortest here, so the curve is a series of spikes rather than an accumulating level.
Research schedule reference
Reported schedule context for Sermorelin; not a plan to start or adjust personal use.
These are commonly-discussed research protocols shared for educational reference. Study amounts apply to the source's population, formulation, and oversight; they do not establish personal suitability. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Typical blockA very short-acting GHRH analog, timed at night to match natural GH release. | 100–500 mcg | Once daily | SubQ, before bed |
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 0.98× single dose
- Time to steady state
- 1hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Sermorelin GH-axis literatureA GHRH(1–29) analog historically used to probe growth-hormone secretion.